Hi all
pretty new to all this. I have pumped some into Deltex - looks like a strong product with good growth. Could be a steady gainer.
Does anyone else have this, and anyone have some research on it? Someone with more experience than me!
thanks in advance.
Grajul

NIHR HTA programme up date.
It appears that although the next stated update from the last (13/01/09) was to be today, but for some reason an update was published on 16/01/09.
The good news is the project at the top of the list now has a estimated publish date of Jan 2009, whereas a few weeks ago such dates were Jan 2008, so somewhat out of date (I would like to think my e-mail giving a diplomatic kick up the ass did it, but I doubt it very much).
The point is since the 13th, seven projects have been published leaving Deltex Cardio now 8th on the projected publishing timescale (from 14th a week ago).
Might not mean much but at least their (Deltex) project is moving nearer the top in priority.
Will post further update after market close tonight.
Hope I'm not going to deep re this (boring) but I feel the result of this project research paper will be a main catalyst in the take up of the Cardio system in the UK.

Note. I am now signed up with the NIHR HTA programme so will be informed of any updates as and when they occur. I will also receive notification as/when the Deltex project is published, so will post immediately, although there will probably be a RNS at the same time.

greekman---------not at all boring, always look forward to your posts, and with DEMG moving up the ladder it looks promising, from what I recall the vast majority of DEMG rns's have been positive anyway, and I don't think that will change now, this is a must have for hospitals worldwide, and for the NHS it should attain Standard of Care status at some point.
2517

Thanks George,

The close of market update from CAP is only a change of date re next update is 20/01/09.
For some reason the Deltex Project has slipped down the priority publication list from 8th this morning to the 16th. So it appears that there are now another 8 projects that have an earlier projected publication date. Not reading too much into this as many projects may be far simpler in discipline and technology to deal with.
Also a couple of projects awaiting publication have now been published ahead of others that were above them in the list. So it appears events such as this are common place. Due to this I will look at the list in a different light of importance.
Also if the only updates in the future are limited to a change of date, I will not post such info unless it is relevant.

Greek.

From the Pre close update.

Several snippets of hope for future sales.
The bits I like are....made significant progress in all of its key markets
for the third consecutive year.......group probe sales in each quarter were ahead of the corresponding quarter in the preceding year.......International sales and marketing operations contributed to a sustainable reduction in the level of underlying cash burn.......reduce or defer wherever possible the majority of such discretionary expenditure until the Company's expected continuing growth.

The future is looking better than ever.

There is so much to like about the progress being made, the spanish operation(sorry about that) look excellent (close to being a standard of care) as does the USA, and with Germany just starting out the sale of probes is still in it's infancy really, and as more hospitals take up the Cardio-Q so the sale of probes should increase substantially. Deferring spending on discretionary items makes sense in the current climate, however I believe this may be to DEMG's advantage, as healthcare spending restrictions are implemented so the adoption of the Cardio-Q becomes more compelling, as it's proven to be more cost effective to use.
2517

Down 6.25% this am (75p). Tempted to invest more but already have Deltex as a very large percentage of my share portfolio, so will probably resist. Although looking cheep at this price, remember there is no such animal in the stock market world as a sure thing.

The report is out an it is not good. Also the conclusion is unbelievable and appears the findings contradict the conclusion.

Headline.

Study found that, although esophageal Doppler monitoring is likely to be of both clinical and economic benefit in high-risk surgical patients, insufficient evidence is available to recommend its widespread use in critically ill patients.

For further in go to...

Sorry will not allow me to edit post MoneyAm faulty yet again.
Link is http://www.hta.ac.uk/execsumm/summ1307.shtml

This extract says it all.

Data sources
Searches of electronic databases [including MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and the Cochrane Library] and relevant websites until May 2007 were undertaken to identify published and unpublished reports, including previous systematic reviews.

So no evidence was examined since May 2007. Marvellous isn't it.
Because these reports sit gathering in-tray dust, any published title is often as this one is almost 2 years out of date
Lets just hope Deltex put forward a follow up project request, as from those reports post May 2007 appear to have answered many of this projects questions.
Of course this would mean another wait of many months.

Apologies to all.

I have now read the full report in detailed study whereas before I read it with less depth analysis due to the disappointing headline, ( I admit to frustration getting the better of me).

The report as I read it is actually more positive than negative.

What do others think?

Be interesting to see how the market(institutional investors) see it.

It took some reading but I believe the outcome is favourable for DEMG, some areas were unaminously positive for the usage of the ODM, whilst others (thinking mortality rates here) were inconclusive due to the limited number of patients being studied/monitored. Cost effectiveness also appeared inconclusive due to a complete lack of in depth study by those doing the research, it seems they need to price up the extra labour costs involved without the ODM, against the cost effectiveness with the ODM, ie how much money is saved due to less complications and shorter hospital stays.

Summing up I think some of the benefits of using the ODM were pinpointed, but to me those carrying out this study have only done half a job because they have not compared the costs involved sufficiently. aimo of course.
2517

Hi George,

Yes it did take some reading. I have now read it three times, the last time putting certain points to my wife, a retired Nurse with intensive care experience.
Between us we sorted it all out (well almost anyway). We came to the same conclusion as yourself.
Cost effectiveness looks as being the main section that has been covered only since May 2007, with no post project date or trial figures information considered, due to the commencement date of the project start.

Off subject but an example of procrastination in anything official.
In Yorkshire we were one of the areas that suffered in the floods of June 2007, the house opposite was flooded out for over 6 months and others were still out after 18 months. Luckily our house in on a slope so we were OK.
My point is the flood survey took several months to set up, and many more months to be finalised and has only now been put to the final decision committee (council), some 18 months from the flood date. One statement has been released. The areas flooded will be prone to further flood risk if nothing is done.

Sorry again re going off thread but just an example of highly paid so called experts twiddling their thumbs whilst people are flooded out (or even more importantly dying) from lack of decisions such as the use of CardioQ.

RNS out re report.

Deltex are putting a posative slant on the report.
The following extract of the RNS shows why.

'The NIHR report will be a very powerful tool in the hands of the many UK doctors already wanting to incorporate use of the CardioQ-ODM into their practice. Combined with new consensus guidelines on fluid management for surgical patients, the Centre for Evidence-based Purchasing report published last year and the recommendations of the NHS National Technology Adoption Centre's work with CardioQ-ODM due later this year, we are building a substantial body of independent NHS recommendations for the wide-scale adoption of the CardioQ-ODM.
'Much of the further research recommended by NIHR is already in hand. We expect that such additional research will make it increasingly difficult for any hospital to not implement ODM as a standard of care for major surgery.'

Only just read the RNS re loan notes.

The only time I feel fund raising as a full benefit to any company is when it is deemed to be for the right reasons, IE to enable a company to push forward as stated, 'The new capital would strengthen its balance sheet during current difficult economic times and allow it to move ahead more quickly on certain initiatives, particularly in establishing ODM in Spain'.

Obviously if Deltex could push forward as it intends without such fund raising, that would be the best scenario, but at the stage Deltex is as a company I would sooner see cash raised with it's associated risk for the aforementioned reasons than for them to plod along struggling to progress due to shortage of capital. Also as others have said, any success in raising capital in the present situation shows someone has confidence in the company.

A risk (hopefully) worth taking.

President Obama has stated he is looking to cut costs in health care (in general).
Cost cutting is usually a blow to any company connected with the business/service being cut.
But looking at this from companies such as Deltex who have innovations that can cut cost due to both times spent in hospitals and less re admissions this could be a very positive step.

Just look at this brief extract from the leading USA papers.

'The biggest chunk would come from a proposal to cut payments the government makes to insurance companies that provide care for those in Medicare under what is known as Medicare Advantage. Obama also wants to cut costs by reducing the amount that Medicare pays hospitals with high re-admission rates, a move that is part of a broad plan to improve care'.

Note the comment 'high re-admission rates and payments to insurance companies'.

The future of medical treatments world wide must be focusing more on cutting costs, especially in the field of private medicine where funding is by insurance premiums.
A few years ago many such private schemes were fleeced by hospitals keeping patients 'that extra' night, therefor receiving that bit more cash/profit. (I know that due to having medical experience relations).
No doubt these same hospitals will be squeezed by these same insurance companies.
I have read several report of late that many patients who go private are looking either for less expensive schemes or leaving such schemes altogether.
No doubt the medical market, like all markets will respond.
Come on you medical/health companies wake up and see the light.

After further though........I wonder if reading between the lines re Spain and this fund raising, they are very close to a big order that as per market rules and the possibility of confidentiality with their Spanish customers they are limited to what they can say.
Of course any financial body (Noble AIM VCT Plc) would want evidence of purpose either present (contract for example) or solid potential in order to consider any loan returns, so I would think sufficient details/information would be allowed between the two participating bodies on a confidentiality agreement.
I appreciate that reading between the lines so to speak is more pot luck than science. I just hope I am not reading too much into this, due to the natural leaning of wanting to see good news rather than bad.
Time will tell.

Good results as long as punters read them with a look to the future in mind. All figures good, except of course the increase in operating loss which was to be expected. With this new funding now available it does look like the next 12/18 months will be very foretelling, hopefully in a positive way. My biggest fear over last year was possible overstretch, something that has now been eliminated (at least for some time) with that increase in capital now obtained.
On a final note I expect the sp to dip just a tad further before it picks up again, purely due to the peculiar, but understandable market mentality we are experiencing.

Getting lonely here. Is there anyone out there apart from me and George.

Hi Greekman,

I thought I would just post so you know you are not alone.
Thanks. I was beginning to wonder if I was the only investor left in Deltex. I think George has gone into hibernation for the winter.
Possibly. I am still fairly heavy into the company.
Yes, so am I, easily the biggest percentage of my share portfolio.
Looking to top up within next couple of months.
Same here. Thanks for posting. I was beginning to think I was going a bit funny as I was starting to imagine things.
What like taking to yourself.
Yes, exactly.

On a serious note, I will continue to post as often reading back through the thread, I remind myself of why I bought into and am still in Deltex.

greekman----been away recharging my batteries for a few days, just seen the results, the message IS getting through ( increase in sales of both monitors and probes), like we have said so many times, it's just a matter of time, and with B. Obama wanting to cut back on health costs DEMG looks ideally placed to benefit.
2517

Hi George,

Agree. Thanks for the post. Sane again, for the time being at least.